ASTRO: Hypofractionated Radiation Therapy Safe After Breast Reconstruction
By Elana Gotkine HealthDay Reporter
WEDNESDAY, Oct. 2, 2024 -- For patients undergoing breast reconstruction, a 16-fraction course of hypofractionated postmastectomy radiation therapy (PMRT) is noninferior to a 25-fraction conventional course, according to a study presented at the annual meeting of the American Society for Radiation Oncology (ASTRO), held from Sept. 29 to Oct. 2 in Washington, D.C.
Matthew M. Poppe, M.D., from the Huntsman Cancer Institute at the University of Utah in Salt Lake City, and colleagues enrolled breast cancer patients with unilateral larger tumors (pT3N0) or smaller tumors and invasion of the regional lymph nodes (pT0-2 pN1-2) who were planning delayed or immediate breast reconstruction and PMRT. Patients were randomly assigned to receive 50.0 Gy in 25 fractions (conventional PMRT) or 42.56 Gy in 16 fractions (hypofractionated PMRT), delivered five days per week (422 and 403 patients, respectively). Patients from 209 centers in the United States and Canada were enrolled from 2018 to 2021 and were followed for a median of 4.5 years.
Of the 650 patients who completed reconstruction, 45 and 55 percent had immediate and delayed breast reconstruction, respectively; 59 and 41 percent had implant alone and autologous +/− implant, respectively. The researchers found that the 24-month incidence of reconstruction complications was 14 and 12 percent with hypofractionation and conventional PMRT, respectively (estimated difference, 2.3 percent, which met the noninferiority margin of 10 percent). Regardless of arm, there was a decrease seen in the complication rate with autologous versus implant-only reconstruction (odds ratio, 0.504). There was no significant difference in acute and late toxicity rates between the arms. Three-year local or regional recurrences occurred in 1.5 and 2.3 percent of hypofractionated and conventional patients, respectively.
"The results of this trial show we can safely reduce treatment time for these patients to three weeks, without compromising their reconstruction," Poppe said in a statement.
Several authors disclosed ties to the biopharmaceutical industry.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted October 2024
Read this next
Odds of Advanced Cancer, Breast Cancer Death Lower in Screen-Detected Disease
THURSDAY, June 5, 2025 -- For patients aged 40 years or older, screen-detected breast cancer is associated with lower odds of advanced cancer, mastectomy, and breast...
ASCO: Durvalumab Plus FLOT Beneficial for Resectable Gastric, GE Junction Cancer
THURSDAY, June 5, 2025 -- For patients with resectable gastric or gastroesophageal junction adenocarcinoma, durvalumab plus fluorouracil, leucovorin, oxaliplatin, and docetaxel...
Nodal Irradiation Does Not Reduce Recurrence, Death for ypN0 Breast Cancer
THURSDAY, June 5, 2025 -- For patients with node-positive breast cancer who become pathologically tumor-free with negative axillary nodes (ypN0) after neoadjuvant chemotherapy...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.